GSK3β conditional transgenic mouse:: A unique model for Alzheimer's disease and other tauopathies

被引：0
|
作者：
Medina, M [1 ]
Martín-Aparicio, E [1 ]
Fuertes, A [1 ]
Pérez-Puerto, MJ [1 ]
Pérez-Navarro, D [1 ]
Martínez, A [1 ]
机构：
[1] NeuroPharma, Tres Cantos, Madrid, Spain
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
10.1016/S0197-4580(04)80850-9
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S253 / S253
页数：1
相关论文
共 50 条
  • [31] Crosstalk between Cdk5 and GSK3β: implications for Alzheimer's disease
    Engmann, Olivia
    Giese, Karl Peter
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2009, 2
  • [32] GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression
    Platenik, Jan
    Fisar, Zdenek
    Buchal, Richard
    Jirak, Roman
    Kitzlerova, Eva
    Zverova, Martina
    Raboch, Jiri
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2014, 50 : 83 - 93
  • [33] Current strategies for the treatment of Alzheimer's disease and other tauopathies
    Dickey, Chad A.
    Petrucelli, Leonard
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (05) : 665 - 676
  • [34] Transgenic mouse models for Alzheimer's disease:: the role of GSK-3β in combined amyloid and tau-pathology
    Muyllaert, D.
    Terwel, D.
    Borghgraef, P.
    Devijver, H.
    Dewachter, I.
    Van Leuven, F.
    REVUE NEUROLOGIQUE, 2006, 162 (10) : 903 - 907
  • [35] Blockage of GSK3β-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease
    Yan, Jing
    Liu, Xiang-Hua
    Han, Ming-Zhi
    Wang, Yu-Meng
    Sun, Xu-Lu
    Yu, Nuo
    Li, Ting
    Su, Bo
    Chen, Zhe-Yu
    NEUROBIOLOGY OF AGING, 2015, 36 (01) : 211 - 227
  • [36] Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer's disease
    Karati, Dipanjan
    Meur, Shreyasi
    Roy, Souvik
    Mukherjee, Swarupananda
    Debnath, Biplab
    Jha, Sajal Kumar
    Sarkar, Biresh Kumar
    Naskar, Saheli
    Ghosh, Priya
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 2319 - 2342
  • [37] The PI3K/AKT/GSK3β pathway is not involved in early Alzheimer's disease
    Lim, J.
    Engel, M.
    Witting, P.
    Ooi, L.
    Sutherland, G.
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 325 - 325
  • [38] GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals
    Hu, Shuxin
    Begum, Aynun N.
    Jones, Mychica R.
    Oh, Mike S.
    Beech, Walter K.
    Beech, Beverly Hudspeth
    Yang, Fusheng
    Chen, Pingping
    Ubeda, Oliver J.
    Kim, Peter C.
    Davies, Peter
    Ma, Qiulan
    Cole, Greg M.
    Frautschy, Sally A.
    NEUROBIOLOGY OF DISEASE, 2009, 33 (02) : 193 - 206
  • [39] Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulfhydrating GSK3β and inhibiting Tau hyperphosphorylation
    Giovinazzo, Daniel
    Bursac, Biljana
    Sbodio, Juan, I
    Nalluru, Sumedha
    Vignane, Thibaut
    Snowman, Adele M.
    Albacarys, Lauren M.
    Sedlak, Thomas W.
    Torregrossa, Roberta
    Whiteman, Matthew
    Filipovic, Milos R.
    Snyder, Solomon H.
    Paul, Bindu D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (04)
  • [40] GSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's disease- like filaments
    Chakraborty, Pijush
    Purslow, Jeffrey A.
    Fromm, Simon A.
    Chatterjee, Debdeep
    Zachrdla, Milan
    Zhuang, Shannon
    Puri, Sambhavi
    Wolozin, Benjamin
    Zweckstetter, Markus
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (52)
12345